|
VDP: BOD resolution dated October 19, 2022 The Board resolution dated October 19, 2022, the BOD of Vidipha Central Pharmaceutical Joint Stock Company approved the following issues:
1. Approved the business result in nine months of 2022:
- Total revenue: 774.322 billion dongs (reached 81% plan of year)
- Revenue from production: 729.990 billion dongs (reached 85% plan of year)
- Profit before tax: 66.415 billion dongs (reached 81% plan of year)
- To pay the State budget: 20.632 billion dongs (reached 51.6% plan of year).
2. Approved the business plan in Quarter 4/2022:
- Total revenue: 190 billion dongs
- Revenue from production: 185 billion dongs
- Profit before tax: 18.585 billion dongs
- To pay the State budget: 10 billion dongs.
3. Approved the business plan in 2023:
a. Option 1:
- Total revenue: 1.000 billion dongs
- Revenue from production: 920 billion dongs
- Profit before tax: 85 billion dongs
b. Option 2:
- Total revenue: 1.050 billion dongs
- Revenue from production: 1.000 billion dongs
- Profit before tax: 90 billion dongs.
4. Approved the first cash dividend payment in 2022:
- Ex-right date: November 28, 2022
- Record date: November 29, 2022
- Exercise ratio: 10%/par value (1,000 dongs/share)
- Payment date: December 15, 2022. HOSE
|
